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Abstract 
Choroid plexus papillomas (CPPs) are usual-
ly not malignant and occur in less than 1% of
brain tumors in patients of all ages. They repre-
sent 3% of childhood intracranial neoplasms
with a predilection in younger ages. Papillomas
have an indolent course and carry a good long-
term outcome if gross total surgical resection is
achieved. However malignant evolution may
occur, with a 10-30% incidence. Chemotherapy
has been used with varied degrees of success.
Most series are very small, some are only limit-
ed to case reports and cannot lead to guidelines
or therapeutic recommendations. We are
reporting the first case of recurrent CPP treated
with 5 mg/kg of bevacizumab administered once
every two weeks. Complete patient evaluations
with follow-up contrast-enhanced magnetic res-
onance imaging (MRI) scans were obtained
after the initial two treatments and every 8
weeks thereafter. Only after two treatments, the
MRI scans showed radiological stabilization of
the tumor, and the patient achieved an excellent
clinical response with significant resolution of
all skin lesions. 
Introduction
Choroid plexus papillomas are usually indo-
lent and occur in less than 1% of brain tumors
in patients of all ages.1 They represent 3% of
childhood intracranial neoplasms with a
predilection in younger ages,1,2 70% occurring
in children less than 2 years old.3-5
Choroid plexus tumors are graded based on
the World Health Organization (WHO) classifi-
cation scheme and include choroid plexus
papilloma (CPP, WHO grade I), atypical choroid
plexus papilloma (APP, WHO grade II), and
choroid plexus carcinoma (CPC, WHO grade
III).6 Papillomas have an indolent course and
carry a good long-term outcome if gross total
surgical resection is achieved.1 However,
malignant evolution may occur, with a 10-30%
incidence.2,7,8 Choroid plexus carcinomas are
typically malignant, aggressive tumors that
have 5-year survival rates reported to be
around 40%.9
Histological appearance is not always pre-
dictive of biologic behavior. Some highly
anaplastic choroid plexus tumors can be clini-
cally benign, whereas some histologically inac-
tive tumors are invasive.1,7,10,11 When malig-
nant degeneration occurs, these tumors tend
to behave like carcinomas and carry a dismal
prognosis, with a 5-year survival rate of 26%
(Figure 1).1,7,11
Adjuvant radiation therapy has been used in
small series and reported to achieve acceptable
long-term control when used in subtotally
resected tumors.11-13
Case Report
A 40-year-old woman was referred to us for
salvage treatment. She was diagnosed in
February 2005 with a 6.5 cm right occipital
tumor with small millimetric parenchymal
metastases and drop metastases throughout
the neuraxis. She presented with clinical evi-
dence of increased intra-crania pressure
(ICP), mass effect with extensive vasogenic
edema requiring urgent surgery. She under-
went gross tumor resection and pathology
reported an atypical choroid plexus papilloma.
Her staging work up was obtained following
her recovery including brain and full spine
contrast enhanced magnetic resonance imag-
ing (MRI) scans. This revealed small drop
metastases in the posterior fossa and along the
spinal cord. The patient received radiation
therapy to the neuraxis (the CSI dose was 36
Gy and the total dose to the primary tumor bed
or surgical cavity was 54 Gy). She remained
clinically stable for two years, and was able to
perform activities of daily living. Repeated con-
trast enhanced MRI scans of the brain and full
spine reported stable appearance in size and
enhancement of all drop metastases in the pos-
terior fossa and the spinal canal.
At relapse, she presented with continuous
headaches, neck stiffness, altered mental sta-
tus, and severe ataxia. Imaging revealed metas-
tasis to bilateral cerebello-pontine (CP) angles
and intraparenchymal supratentorial lesions
(left frontal, right thalamic, and right temporal).
She received 2 cycles of nitrosourea without
response and worsening symptoms. Hence this
was changed to ifosfamide, carboplatin and
etoposide based combination. Radiological and
clinical stabilization were attained following
three cycles, but second progression was docu-
mented after the fifth cycle. Further surgeries
and performed for rapidly growing and sympto-
matic right CP angle metastasis and dorsal
brain stem metastasis. Post-operative imaging
revealed decrease size of the tumor. With
remaining residual disease, the patient was
referred to us for salvage treatment. 
In this setting of previous craniospinal irra-
diation, significant chemotherapy toxicity, and
only short-lived stabilization of the disease,
bevacizumab was offered as single agent treat-
ment in an attempt to spare the patient further
toxicities. The first treatment was injected
after 8 weeks from last surgery.
The patient received bevacizumab, 5 mg/kg
on day 1 and day 15 of each cycle. Cycles were
repeated every 4 weeks. Contrast enhanced
MRI scans were obtained after the initial two
treatments and every 2 cycles thereafter or
sooner if required to assess new or worsening
symptoms. 
The patient was taken off steroids, which
was started at first relapse, shortly after start-
ing bevacizumab and did not receive steroids
later during the course of her disease. Her
symptoms immediately stabilized following the
first cycle of bevacizumab and progressively
improved. The headaches resolved, the mental
status returned to normal, and the ataxia
improved very slowly but her cervical pain and
stiffness did not. She achieved radiological sta-
bilization with significant decrease of the
vasogenic edema, and minimal decrease in the
size and enhancement of all metastatic lesions
(Figures 2 and 3). This response continued for
over 5 months of therapy. A total of five cycles
of bevacizumab were administered (10 treat-
ments). An elective cerebello-pontine angle
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metastasis resection was opted to relieve her
debilitating neck stiffness. 
The postoperative course was complicated
by respiratory failure requiring tracheostomy,
although there was no evidence of disease pro-
gression. The patient died form pulmonary
infection, in turn complicated by severe sepsis. 
Discussion
Choroid plexus tumors typically grow within
the choroid plexus tissue. A gross total resec-
tion is thought to be curative in CPP.
Recurrences are infrequent and the prognosis
is good.14 APPs represent a novel intermediate-
grade subtype of CPT. Its clinical features and
treatment outcomes have not been well estab-
lished in the literature. Several studies have
suggested that adjuvant therapy, radiation
alone, or radiation along with chemotherapy
decreases the incidence of local recurrence
and improves long-term survival.15-17
Chemotherapy has been used with varied
degrees of success. Pediatric protocols com-
bining cisplatin and etoposide;2 cyclophos-
phamide, cisplatin and Vincristine;12 ifos-
famide, carboplatin and etoposide,18 or more
complex regimens,11-13 such as the POG (alter-
nating courses of cisplatin/etoposide and
cyclophosphamide/vincristine, followed by
radiation).12 Nevertheless most series are very
small, some are only limited to case reports
and cannot lead to guidelines or therapeutic
recommendations. 
In this particular case, two lines of
chemotherapy had failed, and poor marrow
reserve secondary to craniospinal radiotherapy
in an adult patient (36 Gy of craniospinal irra-
diation and 54 Gy to the cranium) prevented
further delivery of cytotoxics. Furthermore she
has received and failed two chemotherapy
lines: single agent nitrosourea and combina-
tion of ifosfamide, carboplatin and etoposide. 
Experts characterized CCPs with extraordi-
nary degree of vascularity.19 Recent pathologi-
cal findings identified most Atypical CCP to be
highly vascularized lesions.20 In addition to the
vascularized nature of CCPs, the choice of
therapy was based on the widely disseminated
disease and the extensive vasogenic edema
requiring high doses of steroids to maintain a
good quality of life. Moreover, the lack of sig-
nificant toxicities of bevacizumab made it
somehow attractive. This option was discussed
with the patient, who signed an informed con-
sent, and was approved by the ethical commit-
tee of our institution.13
A lengthy literature search did not yield any
case of choroid plexus tumors treated with
bevacizumab; we are reporting the first case.
Although there was only minimal radiological
improvement, bevacizumab seems to have
                             Case Report
Figure 3. Post contrast T1-weighted axial images of the brain showing stable appearance
of the metastases over 5 months of therapy. Despite the difference in technique between
these imaging studies a minimal reduction in size of the tumor deposits can be noticed
with additional therapy.
Figure 2. Post contrast T1-weighted axial images of the brain showing bilateral cerebello-
pontine angle drop metastases. The difference in technique accounts for the different
image levels.
Figure 1. Choroid Plexus Papilloma with atypical features; there is mild to moderate cyto-
logical atypia, scattered mitoses and an elevated index of proliferation, but without defi-
nite features of malignancy such as cellular anaplasia, tumor necrosis, endothelial cell
proliferation or high mitotic activity. 
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some activity in this subtype of richly vascular-
ized tumors and may be worth further evalua-
tion in combination with chemotherapy.
Conclusions
Single agent bevacizumab has achieved sta-
bilization of the disease during the 5 months
of therapy and three months later on off thera-
py. Cases of CPTs are scarce and there are no
treatments guidelines. A multicenter collabo-
rative trial combining bevacizumab to
chemotherapy may be worth further evaluation
for CPTs earlier during the treatment course. 
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